TrialEuropean heart journal2020

Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial.

Michael Szarek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.